Aptamers as Diagnostic Tools in Cancer

Dario Ruiz Ciancio; Mauricio R Vargas; William H Thiel; Martin A Bruno; Paloma H Giangrande; María Belén Mestre

doi:10.3390/ph11030086

Back

Journal article

Open access

Peer reviewed

Aptamers as Diagnostic Tools in Cancer

Dario Ruiz Ciancio, Mauricio R Vargas, William H Thiel, Martin A Bruno, Paloma H Giangrande and María Belén Mestre

Pharmaceuticals (Basel, Switzerland), Vol.11(3), p.86

09/01/2018

DOI: 10.3390/ph11030086

PMCID: PMC6160954

PMID: 30208607

Files and links (1)

url

https://doi.org/10.3390/ph11030086View

Published (Version of record) Open Access

Abstract

Cancer is the second leading cause of death worldwide. Researchers have been working hard on investigating not only improved therapeutics but also on early detection methods, both critical to increasing treatment efficacy, and developing methods for disease prevention. The use of nucleic acids, or aptamers, has emerged as more specific and accurate cancer diagnostic and therapeutic tools. Aptamers are single-stranded DNA or RNA molecules that recognize specific targets based on unique three-dimensional conformations. Despite the fact aptamer development has been mainly restricted to laboratory settings, the unique attributes of these molecules suggest their high potential for clinical advances in cancer detection. Aptamers can be selected for a wide range of targets, and also linked with an extensive variety of diagnostic agents, via physical or chemical conjugation, to improve previously-established detection methods or to be used as novel biosensors for cancer diagnosis. Consequently, herein we review the principal considerations and recent updates in cancer detection and imaging through aptamer-based molecules.

diagnosis

cancer

Review

aptamer

imaging

Details

Title: Subtitle: Aptamers as Diagnostic Tools in Cancer
Creators: Dario Ruiz Ciancio - Biomedical Science Institute (ICBM), Catholic of Cuyo University, San Juan, CP 5400, Argentina
Mauricio R Vargas - Biomedical Science Institute (ICBM), Catholic of Cuyo University, San Juan, CP 5400, Argentina
William H Thiel - Department of Internal Medicine, University of Iowa, Iowa City, IA 52246, USA
Martin A Bruno - Biomedical Science Institute (ICBM), Catholic of Cuyo University, San Juan, CP 5400, Argentina
Paloma H Giangrande - Department of Internal Medicine, University of Iowa, Iowa City, IA 52246, USA
María Belén Mestre - Biomedical Science Institute (ICBM), Catholic of Cuyo University, San Juan, CP 5400, Argentina
Resource Type: Journal article
Publication Details: Pharmaceuticals (Basel, Switzerland), Vol.11(3), p.86
DOI: 10.3390/ph11030086
PMID: 30208607
PMCID: PMC6160954
NLM abbreviation: Pharmaceuticals (Basel)
ISSN: 1424-8247
eISSN: 1424-8247
Publisher: MDPI
Language: English
Date published: 09/01/2018
Academic Unit: Cardiovascular Medicine; Radiation Oncology; Internal Medicine
Record Identifier: 9984094552002771

Metrics

41 Record Views

73 Times Cited - Web of Science